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Background: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung
cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed
to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy.
Methods: Adults with stage IIIb/IV NSCLC in whom one or more chemotherapy regimen had failed were treated with
erlotinib (150 mg/day). Tumour biopsies were analysed using gene expression profiling with Affymetrix GeneChip
microarrays. Differentially expressed genes were verified using quantitative RT–PCR (qRT–PCR).
Results: A total of 264 patients were enrolled in the study. Gene expression profiles found no statistically significant
differentially expressed genes between patients with and without clinical benefit. In an exploratory analysis in
responding versus nonresponding patients, three genes on chromosome 7 were expressed at higher levels in the
responding group [epidermal growth factor receptor (EGFR), phosphoserine phosphatase (PSPH) and Rap guanine
nucleotide exchange factor 5 (RAPGEF5)]. Independent quantification using qRT–PCR validated the association
between EGFR and PSPH overexpression, but not RAPGEF5 overexpression, and clinical outcome.
Conclusions: This study supports the use of erlotinib as an alternative to chemotherapy for patients with relapsed
advanced NSCLC. Genetic amplification of the EGFR region of chromosome 7 may be associated with response
to erlotinib therapy.
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introduction
Erlotinib, an orally available epidermal growth factor receptor
(EGFR) tyrosine-kinase inhibitor (TKI), significantly prolongs
survival and produces significant symptom and quality-of-life
benefits compared with best supportive care in unselected
patients with relapsed non-small-cell lung cancer (NSCLC)
[1, 2]. In a large, phase III, placebo-controlled study (BR.21),
erlotinib produced a survival benefit across all patient
subgroups studied [1].
Considerable research has been undertaken to identify
molecular markers that predict sensitivity to EGFR TKIs. The
most extensively studied potential markers are EGFR protein
expression level, EGFR gene copy number and EGFR gene
mutations [3–7]. Post hoc molecular analyses of samples from
the BR.21 study found increased EGFR gene copy number to
be the only significant molecular predictor of a differential
survival benefit from treatment with erlotinib [8]. Recently,
a prospective biomarker analysis carried out for erlotinib as
part of the phase III, randomised, placebo-controlled
Sequential Tarceva in Unresectable NSCLC (SATURN) study
showed that maintenance erlotinib produced a progression-
free survival (PFS) benefit in all patients, irrespective of the
status of candidate biomarkers investigated; however, those
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with EGFR mutations had a particularly notable extension
of PFS [9].
Identification of molecular markers that predict sensitivity to
erlotinib should facilitate the appropriate selection of NSCLC
patients who are most likely to benefit from treatment. The
primary objective of the phase II Marker Identification Trial
(MERIT; BO18279) was to identify candidate genes
differentially expressed between patients who did and did not
obtain clinical benefit from erlotinib therapy.
methods
study design and patients
This was a nonrandomised, open-label, multicentre, phase II study. Patients
aged ‡18 years with histologically or cytologically confirmed stage IIIb/IV
NSCLC in whom one or more prior chemotherapy regimen had failed or
who were unsuitable or unwilling to undergo such therapy were eligible for
study inclusion. Patients were required to have tumour tissue accessible
for tissue sampling by bronchoscopy; measurable disease according to
RECIST [10]; Eastern Cooperative Oncology Group performance status of
zero to two; life expectancy of ‡12 weeks; adequate renal, hepatic and
haematological function and an interval of ‡4 weeks since previous surgery
or radiotherapy. Patients were excluded from the study if they had any
condition likely to cause undue risk during erlotinib therapy or
bronchoscopy; any previous malignancy in the past 5 years (other than
successfully treated cervical or skin carcinoma); brain metastases or spinal
cord compression that had not been successfully treated or previous
treatment with an EGFR-targeted therapy.
Patients received oral erlotinib 150 mg once daily until disease
progression, unacceptable toxicity or death.
The study was carried out according to the principles of the Declaration of
Helsinki and was overseen by Independent Ethics Committees at the
participating centres.Written informed consentwas obtained fromall patients.
study design
efficacy and safety evaluations. Tumour size was measured by computed
tomography or magnetic resonance imaging at study entry, 6-week intervals
until week 24, and every 12 weeks thereafter, with responses assessed using
RECIST [10]. Complete responses (CRs) or partial responses (PRs) were
confirmed by repeated assessments ‡4 weeks apart at any time during the
treatment period. Disease control was defined as an objective response
(CR/PR) or maintenance of stable disease (SD) for ‡6 weeks after study
entry. Clinical benefit was defined as an objective response (CR/PR) or
maintenance of SD for ‡12 weeks after study entry. PFS was defined as the
time from study entry to the time of documented disease progression or
death (patients still benefiting at the time of analysis were treated as
censored observations). Adverse events were graded according to the
National Cancer Institute—Common Toxicity Criteria, version 3.0.
biomarker analyses. Patients underwent bronchoscopy within 2 weeks before
the start of treatment to provide two tumour samples. If available, diagnostic
tumour blocks were to be provided within 6 weeks of study entry.
gene expression profiling. One tumour biopsy sample from each patient was
snap frozen immediately in liquid nitrogen. At the reference laboratory, initial
RNA quality was determined by extraction of total RNA from one unstained,
unfixed tissue cryosection and analysed using the Agilent RNA 6000 Pico Chip
(Agilent Technologies, SantaClara, CA). If at least one residual ribosomalRNA
peakwas visible on the electropherogram(RNAquality criterion) and sufficient
numbersof tumour cellswerepresent in the selected sections (histopathological
criterion), laser capturemicrodissection (LCM)of tumourcellswas carriedout.
Tumour cells from the cryosections were captured using the PixCell II LCM
instrument (Arcturus) on to CapSure Macro LCM Caps (Arcturus, MDS
Analytical Technologies, Sunnyvale, CA) as described by the manufacturer.
Immediately after LCM, RNAwas extracted from the sample using the RNeasy
Mini Kit (QIAGEN GmbH, Hilden, Germany). A two-cycle linear
amplification protocol (Affymetrix UK Ltd, HighWycombe, UK) was used for
target labelling because of the relatively low yields of RNA from LCM. The
samples were then analysed using GeneChip gene expression profiling
technology with the human genome (HG) U133A chip according to
the manufacturer’s instructions (Affymetrix), to assess the level of messenger
RNA (mRNA) transcripts of the entire genome. The HG-U133A chip consists
of 22 283 ‘probe sets’, covering13 298 genes. Samples of adequate quality for
statistical comparison were selected following quality control using Affymetrix
software MAS 5.0.
quantitative RT–PCR analysis. On the basis of an exploratory analysis of the
Affymetrix gene expression profiling data, three genes, all located on
chromosome 7, were identified for independent assessment of mRNA
transcript levels using quantitative RT–PCR (qRT–PCR): EGFR,
phosphoserine phosphatase (PSPH) and Rap guanine nucleotide exchange
factor 5 (RAPGEF5).
RNA was extracted from fresh frozen tumour tissue and where available
from formalin-fixed paraffin-embedded (FFPE) tumour samples, as
described above. Complementary DNA was synthesised using SuperScript
III First-strand Synthesis SuperMix for qRT–PCR (Invitrogen GmbH,
Karlsruhe, Germany), according to the manufacturer’s instructions, but
without inclusion of an ribonuclease H digest. Quantitative PCR was
carried out using TaqMan Gene Expression Assays on an ABI PRISM
7900HT Sequence Detection System (Applied Biosystems), according to the
manufacturer’s instructions. The gene expression assays used
(Hs01076086_m1 [EGFR], Hs00190154_m1 [PSPH] and Hs00920287_m1
[RAPGEF5]) were chosen so that the primers and probes crossed exon
boundaries or were within the Affymetrix GeneChip probe sequence of
interest. Two housekeeping genes were included as endogenous controls:
b2-microglobulin (b2M) (Assay Hs9999907_m1) and hypoxanthine
phosphoribosyltransferase 1 (Assay Hs9999909_m1). All runs included
a calibrator sample and a standard curve, and all samples were measured in
triplicate. Relative quantification was carried out using the DCt method
using b2M as reference gene [11].
FISH analyses. The second tumour biopsy sample obtained from each
patient by bronchoscopy was fixed in formalin immediately after surgery
and embedded in paraffin. EGFR gene copy number was assessed by FISH,
as described by Schneider et al. [12]. Samples with high gene copy number
(high polysomy/gene amplification) were classed as FISH positive [4]. FISH
analyses were also carried out on diagnostic tumour blocks, if available.
EGFR and KRAS gene mutation analysis. Please refer to supplemental
section (available at Annals of Oncology online) for details of EGFR and
KRAS mutation analyses.
statistical analysis of gene expression profiling data. This study was powered
to realistically identify ‘straightforward’ markers of clinical benefit with
erlotinib. Similar differential expression levels were observed for genes
proposed to be predictive of response to gefitinib [13].
The power calculation was conducted following a simulation scheme as
described by Wang et al. [14], assuming (i) a set of five straightforward
markers of clinical benefit were present (with an area under the curve of
90%) and (ii) that 25% of patients would derive clinical benefit from
erlotinib. A false discovery rate (FDR) cut-off of 5% was used to account for
multiple testing instead of a fixed P value cut-off. Our simulation-based
estimation of the probability of detecting the set of all five markers with
a sample size of 125 was very close to one (>95%). On the basis of an
assumed 50% success rate in obtaining the required quality and quantity of
RNA from tumour samples, target recruitment was set at 250 patients.
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Gene expression data were normalised using the robust multi-array
analysis algorithm library [15], with identification and removal of a batch
effect [16]. The Affymetrix MAS5 algorithm was used to identify probe
sets below the detection limit, and probe sets with ‘absent’ or ‘marginal’
status in all patients were removed from further analysis. Consensus
clustering, using an unsupervised clustering algorithm [17], was applied to
the gene expression dataset to identify patients with similar overall
expression profiles. A linear model was fitted independently to each probe
set, with normalised expression level as dependent variable. In the primary
analysis model for clinical benefit versus no clinical benefit, covariates
included clinical benefit category, histology, ethnicity, sex, RNA integrity
number, smoking status and disease stage. The statistical test of differences
in expression level was assessed using a FDR criterion to account for
multiple statistical testing [18]. A FDR of <0.3 was set as the cut-off.
For qRT–PCR data, boxplot graphical displays were used for the analysis,
with DCt distribution on the y-axis versus RECIST response category on the
x-axis.
results
patients
A total of 264 patients from 26 centres in 12 countries were
enrolled in the study over a 12-month period (Table 1). A total
of 102 tumour samples (the ‘primary analysis set’) were suitable
for gene expression profiling using Affymetrix GeneChip
microarrays. qRT–PCR results were obtained from 75 patients;
among these, 66 also had an Affymetrix profile. The
demographics and clinical characteristics of the patients with
Affymetrix gene expression profiles and qRT–PCR results
were generally similar to those of the entire study population
(Table 1).
clinical outcomes
Among 264 patients, the overall response rate (ORR) was
13.6% (36 PR and 0 CR). SD lasting ‡6 weeks was achieved in
80 patients (30.3%), to produce a disease control rate (DCR)
of 43.9%. A total of 47 (17.8%) patients had SD lasting ‡12
weeks, producing a clinical benefit rate of 31.4%. Compared
with the overall study population, a lower ORR and DCR were
observed in the subset of patients with Affymetrix gene
expression profiles (6% and 36%, respectively) and the subset
of patients with qRT–PCR results (5% and 36%, respectively).
In the entire study population, median PFS was 11.3 weeks
[95% confidence interval (CI) 8–12 weeks] and median overall
survival was 7.6 months (95% CI 7–9 months). Median
duration of response was 32.1 weeks (95% CI 30–42 weeks).
Erlotinib was generally well tolerated, with no unexpected
safety signals reported.
gene expression profiling analyses
A cluster analysis of Affymetrix gene expression profiles
identified three clusters, which discriminated between different
tumour histology types (supplemental Figure 1, available at
Annals of Oncology online) but not clinical benefit status (data
not shown). Gene expression profiles from patients who
obtained a clinical benefit with erlotinib (6 PR and 15 SD ‡12
weeks) were compared with those from patients who did not
benefit [16 SD <12 weeks, 49 progressive disease (PD) and 16
not assessable]. Of the transcripts analysed, none yielded an
FDR value <0.3 (supplemental Figure 2, available at Annals of
Oncology online), indicating that no strong single predictor
of clinical benefit existed. Furthermore, no strong markers of
benefit from erlotinib therapy were found in additional
exploratory analyses on the basis of different definitions of
clinical benefit (including PR + SD versus PD, PFS £6 weeks
versus PFS ‡24 weeks and PFS overall), response to previous
treatment, analysis by gene sets or grouping by biological
pathway or chromosomal location.
However, three genes were found to be expressed at different
levels (FDR <0.3) when comparing the expression profiles of
responding patients (six PR) with those of patients with early
disease progression (n = 49) or who were not assessable
(n = 16): EGFR (7p11.2; FDR = 0.12, P = 0.00002); PSPH
(7p12; FDR = 0.07, P = 0.000006) and RAPGEF5 (7p15.3;
FDR = 0.07, P = 0.000009) (supplemental Figure 3, available
at Annals of Oncology online). Expression of these genes was
Table 1. Baseline patient and disease characteristics
Characteristic All patients Primary analysis
set (patients with
Affymetrix gene
expression analyses)
Patients with
qRT–PCR
analyses
n 264 102 75
Median age;
years (range)
61 (32–85) 62 (39–85) 62 (39–85)
Gender; n (%)
Male 184 (70) 77 (75) 56 (75)
Female 80 (30) 25 (25) 19 (25)
Histology; n (%)
Adenocarcinoma 107 (41) 35 (34) 27 (37)
Squamous cell
carcinoma
101 (38) 50 (49) 34 (45)
Large cell
carcinoma
12 (5) 2 (2) 2 (3)
Other 44 (17) 15 (15) 12 (16)
ECOG PS; n (%)
0 33 (13) 7 (7) 7 (9)
1 169 (64) 69 (68) 45 (60)
2 62 (23) 26 (25) 23 (31)
Disease stage; n (%)
IIIb 69 (26) 27 (26) 22 (29)
IV 195 (74) 75(74) 53 (71)
Ethnicity; n (%)
Caucasian 162 (61) 65 (64) 51 (68)
Asian 101 (38) 37 (36) 24 (32)
Other 1 (<1) 0 (0) 0 (0)
Smoking history; n (%)
Never 72 (27) 20 (20) 12 (16)
Current 71 (27) 33 (32) 24 (32)
Former 121 (46) 49 (48) 39 (52)
Prior chemotherapy regimens for advanced NSCLC; n (%)
0 58 (22) 26 (25) 19 (25)
1 134 (51) 50 (49) 36 (48)
‡2 68 (26) 25 (25) 20 (27)
Unknown 4 (2) 1 (1) 0 (0)
qRT–PCR, quantitative RT–PCR; ECOG, Eastern Cooperative Oncology
Group; PS, performance status; NSCLC, non-small-cell lung cancer.
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2.8-fold, 2.6-fold and 2.0-fold higher, respectively, in
responding patients versus those with early disease progression
or who were not assessable (Figure 1A–C). Although the
control on the number of false positives is not rigorously
guaranteed in such exploratory analyses, additional supportive
evidence came from analyses showing that higher (greater than
median) expression of EGFR, PSPH and RAPGEF5 was
significantly associated with longer PFS on erlotinib therapy
(P = 0.011, P = 0.0017 and P = 0.0058, respectively; Figure 2).
qRT–PCR analysis
As observed with Affymetrix profiling, EGFR mRNA levels
assessed using qRT–PCR appeared to correlate with response to
erlotinib, with higher levels being observed in responders (four
PR) compared with those with best response of SD (n = 23)
or disease progression (n = 39) (Figure 1IIA). The association
between PSPH mRNA levels and clinical outcome with
erlotinib observed in the Affymetrix gene expression data was
preserved in the qRT–PCR data (Figure 1IIB); however, the
association between clinical outcome with erlotinib and
RAPGEF5 mRNA levels assessed by qRT–PCR was somewhat
poorer than that observed with Affymetrix profiling
(Figure 1IIC). In addition, nine patients had mRNA extracted
from matching FFPE tumour samples and analysed by
qRT–PCR. A high correlation was observed between EGFR
mRNA levels in fresh frozen and FFPE tissue (Spearman
r = 0.89).
correlation between Affymetrix GeneChip gene
expression data and EGFR FISH status
In EGFR FISH analyses, 53% (21 of 40) of diagnostic samples
and 61% (54 of 89) of bronchoscopy samples were FISH
positive. There were no tumour responses among patients with
EGFR FISH-negative tumours, although sustained disease
control was observed in some patients in this group, with
clinical benefit rates of 31.6% (six patients) on the basis of
diagnostic samples and 28.6% (10 patients) on the basis of
bronchoscopy samples. The response rate in the FISH-positive
group was 9.5% (two patients) on the basis of diagnostic
samples or 11.1% (six patients) on the basis of bronchoscopy
samples; the corresponding clinical benefit rates were 28.6%
(6 patients) and 31.5% (17 patients).
A significant relationship was observed between EGFR FISH
status and both EGFR and PSPH mRNA levels assessed using
Affymetrix profiling (P £ 0.01 and P < 0.05, respectively), with
higher expression of these genes in EGFR FISH-positive
tumours. A similar trend was noted when EGFR and PSPH
mRNA were assessed using qRT–PCR. There was no significant
Figure 1. Relationships between clinical outcomes and (I) Affymetrix GeneChip gene expression data and (II) quantitative RT–PCR data with erlotinib
therapy for the (A) EGFR gene; (B) PSPH gene and (C) RAPGEF5 gene.
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correlation between EGFR FISH status and RAPGEF5 mRNA
levels as assessed by either Affymetrix profiling or qRT–PCR.
EGFR and KRAS mutation analysis
All six patients with EGFR gene mutations obtained clinical
benefit from erlotinib while 2 of 10 patients with KRAS gene
mutations derived clinical benefit. Please refer to supplemental
section (available at Annals of Oncology online) for details.
discussion
The clinical findings of the MERIT study are consistent with
those observed in the phase III BR.21 study of erlotinib versus
placebo in patients with previously treated advanced NSCLC
[1] and confirm the safety and efficacy of erlotinib in this
disease.
This study is one of the largest global, multicentre, gene-
profiling studies to be conducted in NSCLC to date and shows
the feasibility of carrying out prospective tissue-based analyses
in this patient population. Nevertheless, the difficulties in
obtaining adequate histologic tumour samples in patients with
lung cancer highlight the importance of evaluating new
techniques for tumour sampling, such as cytologic analysis.
The primary objective of the study was the identification of
differentially expressed genes that are predictive for clinical
benefit from erlotinib treatment. Clinical benefit was defined as
objective tumour response or SD lasting ‡12 weeks, which was
considered a relevant efficacy outcome in mainly pretreated
patients with advanced NSCLC, given that SD is an important
factor contributing to the overall survival benefit produced
by erlotinib [1]. The quality of the gene expression profiling
data obtained was confirmed by the discrimination of different
tumour histologies in an unsupervised clustering analysis. The
study was adequately powered to detect genes with a large
difference in mean expression levels between patients with and
without clinical benefit. The primary analysis did not identify
any statistically significant differentially expressed genes,
indicating that it is unlikely that there are any single genes in
NSCLC tumour cells with a large difference in mean expression
levels (at the mRNA level) between patients who derive clinical
benefit from erlotinib therapy and those who do not.
An exploratory analysis revealed three genes (EGFR, PSPH
and RAPGEF5) that were overexpressed in patients achieving
tumour response (PR) with erlotinib therapy versus those with
early disease progression or who were not assessable. The EGFR
and PSPH genes are located very close to each other on
chromosome 7 (positions 7p11.2 and 7p12, respectively). A
recent molecular analysis has indicated that the EGFR region on
chromosome 7 is frequently amplified in lung adenocarcinoma
[19]. Furthermore, in this study, the levels of both EGFR and
PSPHmRNA were significantly associated with high EGFR gene
copy number (assessed using FISH). Taken together, these data
may indicate that EGFR and PSPH could be co-amplified in
a single genetic event focused on the 7p1127p12 region of the
chromosome and that this may play a role in determining
sensitivity to erlotinib.
RAPGEF5 is also located on chromosome 7 but is more
distant from EGFR, being at position 7p15.3. RAPGEF5
encodes a guanine nucleotide exchange factor involved in
intracellular signalling [20, 21], which may provide a potential
link between its up-regulation and increased sensitivity to
erlotinib.
The results of this exploratory analysis were technically
confirmed by assessing EGFR, PSPH and RAPGEF5 mRNA
expression using an alternative technique (qRT–PCR) in
a subset of the same patients. For EGFR, very similar results
were obtained irrespective of the technique used to assess
mRNA levels. This provides further evidence of a link between
EGFR expression level and clinical outcome with erlotinib [22].
Up-regulation of PSPH as assessed by qRT–PCR was also
observed in patients who responded to erlotinib compared with
those who did not. No strong trend was observed for RAPGEF5
expression, however, using this technique. Disparities between
Affymetrix and qRT–PCR results for RAPGEF5 may be due
to its relatively low expression and the greater sensitivity of the
qRT–PCR technique.
Figure 2. Kaplan–Meier analyses of progression-free survival (PFS) according to Affymetrix gene expression of EGFR, PSPH and RAPGEF5. Patients were
grouped according to those with expression levels below the median and above the median.
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In summary, the results of the MERIT study support the use
of erlotinib as an effective and well-tolerated alternative to
chemotherapy for patients with relapsed advanced NSCLC.
Successful completion of this study provides genome-wide
expression data from >100 patients who were treated with
erlotinib. The primary analysis identified no single genes whose
baseline expression in tumour samples is highly predictive of
clinical benefit from erlotinib therapy. However, an exploratory
analysis identified three genes (EGFR, PSPH and RAPGEF5)
whose expression was significantly associated with tumour
response to erlotinib. Independent quantification of the mRNA
of these genes validated the association between EGFR and
PSPH overexpression and clinical outcome, although the
correlation between RAPGEF5 levels and outcome is less clear.
Further validation of these findings is required from
independent studies.
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